Literature DB >> 26264246

Colistin-tigecycline versus colistin-imipenem-cilastatin combinations for the treatment of Acinetobacter baumannii ventilator-acquired pneumonia: a prognosis study.

Anis Chaari1, Tài Pham2,3,4, Basma Mnif5, Kamilia Chtara6, Fatma Medhioub6, Najeh Baccouche6, Mabrouk Bahloul6, Adnène Hammami5, Mounir Bouaziz6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26264246     DOI： 10.1007/s00134-015-4010-z

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  5 in total

1.  Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia.

Authors:  Antonio T Freire; Vasyl Melnyk; Min Ja Kim; Oleksiy Datsenko; Oleksandr Dzyublik; Felix Glumcher; Yin-Ching Chuang; Robert T Maroko; Gary Dukart; C Angel Cooper; Joan M Korth-Bradley; Nathalie Dartois; Hassan Gandjini
Journal:  Diagn Microbiol Infect Dis       Date:  2010-10       Impact factor: 2.803

2.  Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint.

Authors:  Olaf Burkhardt; Kerstin Rauch; Volkhard Kaever; Johannes Hadem; Jan T Kielstein; Tobias Welte
Journal:  Int J Antimicrob Agents       Date:  2009-03-10       Impact factor: 5.283

3.  In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.

Authors:  Marc H Scheetz; Chao Qi; John R Warren; Michael J Postelnick; Teresa Zembower; Arlene Obias; Gary A Noskin
Journal:  Antimicrob Agents Chemother       Date:  2007-02-16       Impact factor: 5.191

4.  Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria.

Authors:  D Plachouras; M Karvanen; L E Friberg; E Papadomichelakis; A Antoniadou; I Tsangaris; I Karaiskos; G Poulakou; F Kontopidou; A Armaganidis; O Cars; H Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2009-05-11       Impact factor: 5.191

Review 5.  Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria.

Authors:  Matteo Bassetti; Jan J De Waele; Philippe Eggimann; Josè Garnacho-Montero; Gunnar Kahlmeter; Francesco Menichetti; David P Nicolau; Jose Arturo Paiva; Mario Tumbarello; Tobias Welte; Mark Wilcox; Jean Ralph Zahar; Garyphallia Poulakou
Journal:  Intensive Care Med       Date:  2015-03-20       Impact factor: 17.440
  5 in total
  2 in total

1.  Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens.

Authors:  Zihan Chen; Xiaoyan Shi
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

2.  Efficacy of intravenous tigecycline in patients with Acinetobacter complex infections: results from 14 Phase III and Phase IV clinical trials.

Authors:  Hal Tucker; Michele Wible; Ashesh Gandhi; Alvaro Quintana
Journal:  Infect Drug Resist       Date:  2017-11-03       Impact factor: 4.003
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.